1/2
Export Ready

ERLOLIEVA 150MG TAB (ERLOTINIB TABLETS IP 150MG)

Sold by RADHAKRUSHNA MEDICALS · Distributor, Exporter, Wholesaler · Yavatmal, Maharashtra, India

Price
Price on request
In stock
Minimum order: 1 Bottle

Export Snapshot

MOQ
1 Bottle
Lead time
On request
Packaging
Standard export packaging
Shelf life / longevity
As per product specification
HSN Code
300490
Origin
India
Port of dispatch
On request
Export markets served
United States flag US Philippines flag PH Smaller Territories of the UK flag XG United Kingdom flag GB Bangladesh flag BD +46 others
Values shown are for RADHAKRUSHNA MEDICALS.
Suitable for

Importers · Distributors · Wholesalers

Know your supplier

RADHAKRUSHNA MEDICALS is a Distributor, Exporter, Wholesaler based in Yavatmal Maharashtra India.

Yavatmal Dispatch on request Verified seller
RADHAKRUSHNA MEDICALS logo

Distributor, Exporter, Wholesaler · Yavatmal, Maharashtra, India

"Radhakrushna Medicals: Your Destination for Critical Care & Speciality Medicines. Surgical Suture Vaccines  "

Registered address: Yavatmal, India. Industry: Healthcare, Medical Supplies & Pharmaceuticals > Drugs & Pharmaceuticals.

Established
2022
Employees
1–10
GST
27AEMPT2491Q2ZF
IEC code
AEMPT2491Q
Export markets
United States flag US Philippines flag PH Smaller Territories of the UK flag XG United Kingdom flag GB Bangladesh flag BD +46 others
GlobalLinker Member Since
Feb 2026
Turnover
$50,000 - $250,000
Incorporation Type
On request
Product details

What are the specifications of this product?

Overview

Erlotinib Tablets IP 150mgBrand Name ERLOLIEVA 150MGComposition Erlotinib Tablets IP 150mgManufacture By Allieva Pharma Private LimitedForm TabletPacking Btl (30 tab)Country Of Origin India

Product Description


Description
ERLOLIEVA contains Erlotinib, an oral targeted anticancer medicine. It is a tyrosine kinase inhibitor (TKI) that selectively blocks the epidermal growth factor receptor (EGFR), thereby inhibiting tumor cell proliferation and survival—especially in EGFR-mutated cancers.

Uses
Erlotinib is used for the treatment of:

Non-small cell lung cancer (NSCLC) – EGFR-mutation positive (first-line or subsequent therapy)

Locally advanced or metastatic NSCLC – after failure of at least one prior chemotherapy regimen

Pancreatic cancer – in combination with gemcitabine

Side Effects
Common side effects:

•  Skin rash (acne-like)

•  Diarrhea

•  Loss of appetite

•  Fatigue

•  Nausea

Serious side effects:

•  Interstitial lung disease (rare but serious)

•  Severe skin reactions

•  Liver enzyme elevation

• Gastrointestinal perforation (rare)

Dosage
•   Standard dose: 150 mg orally once daily

•  Take on an empty stomach
    (At least 1 hour before or 2 hours after food)

•  Dose adjustment may be required based on tolerance or liver function.

NOTE: This medicine should be taken only under a doctor’s supervision.
Prescription Required

Description provided by RADHAKRUSHNA MEDICALS.

Specifications

Formulation Oral Tablet
Strength 150 mg Erlotinib per tablet
Packing Size 30 tablets per bottle
Therapeutic Class Anticancer, Tyrosine Kinase Inhibitor
Targeted Cancer Types Non-small cell lung cancer (NSCLC), Pancreatic cancer
Dosage Instruction Take 150 mg once daily on empty stomach
Side Effects Skin rash, diarrhea, fatigue, nausea, rare interstitial lung disease
Storage Conditions Store in a cool, dry place away from direct sunlight
Regulatory Status Prescription drug - physician supervision required
Manufacturer Location India

Use cases

Category Pharmaceuticals > Anti-Cancer Drugs > Tyrosine Kinase Inhibitors
Primary application Wholesale, distribution, and international sourcing
Brand Not specified
Product type Product

Logistics & handling

Lead time On request
Packaging As per buyer requirement
Storage condition As recommended by supplier
Origin India
Form As listed by supplier

Commercials (this seller)

Minimum order 1 Bottle
Lead time On request
Payment terms As per negotiated commercial agreement.
Buyer questions

Frequently asked by buyers

Common questions B2B buyers ask before sourcing ERLOLIEVA 150MG TAB (ERLOTINIB TABLETS IP 150MG). Answers compiled from verified sellers' commercial terms and platform data.

Q: What cancers is ERLOLIEVA 150MG TAB primarily used to treat?
A: ERLOLIEVA 150MG TAB is primarily used to treat EGFR mutation-positive Non-small cell lung cancer (NSCLC) and in combination with gemcitabine for pancreatic cancer.
Q: What is the recommended dosage and administration guidance for ERLOLIEVA 150MG TAB?
A: The standard recommended dose is 150 mg administered orally once daily on an empty stomach, at least 1 hour before or 2 hours after meals.
Q: Are there specific side effects healthcare providers should monitor with ERLOLIEVA 150MG TAB?
A: Common side effects include skin rash, diarrhea, fatigue, and nausea, but healthcare providers should closely monitor for rare but serious adverse effects such as interstitial lung disease and severe skin reactions.
Q: Is ERLOLIEVA 150MG TAB suitable for first-line treatment?
A: Yes, ERLOLIEVA 150MG TAB can be used as first-line therapy for patients with EGFR-mutated NSCLC or after failure of at least one previous chemotherapy regimen.
Q: What are the storage recommendations for ERLOLIEVA 150MG TAB?
A: It should be stored in a cool, dry place away from direct sunlight to maintain stability and potency.
Question not answered? Ask sellers directly — typical response within 4 hours.
ERLOLIEVA 150MG TAB (ERLOTINIB TABLETS IP 150MG)
ERLOLIEVA 150MG TAB (ERLOTINIB TABLETS IP 150MG)
Price on request · MOQ 1Bottle